Article
Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation.
Cancer chemotherapy and pharmacology - 1 Nov 2014
Igawa Satoshi, Kasajima Masashi, Ishihara Mikiko, Kimura Michiko, Hiyoshi Yasuhiro, Niwa Hideyuki, Kusuhara Seiichiro, Harada Shinya, Asakuma Maiko, Otani Sakiko, Katono Ken, Sasaki Jiichiro, Masuda Noriyuki
Abstract excerpt
BACKGROUND: Exon 19 deletions and L858R point mutation are the most commonly encountered active epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), and they predict greater efficacy of gefitinib therapy. The objective of this study was to evaluate whether body surface area (BSA) affects the efficacy of gefitinib in patients with NSCLC harboring an active EGFR mutation....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.